Ying Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ying Ma has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jesse Zhu
Department of Chemical and Biochemical Engineering, The University of Western Ontario, London, ON N6A 5B9, Canada
3 shared publications - Binjie Hu
Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo, China
2 shared publications - Xiaoyang Wei
China Beacons Institute, University of Nottingham Ningbo China, Ningbo, China
2 shared publications - Yuanyuan Shao
University of Nottingham Ningbo China
2 shared publications - Yuqing Ye
Department of Biomedical Engineering University of Western Ontario London Ontario Canada
2 shared publications - Zhewei Liu
Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo, China
2 shared publications
Latest Publications
- Open Access
Development of an AI-Empowered Novel Digital Monitoring System for Inhalation Flow Profiles
The use of dry powder inhalers (DPIs) represents a cornerstone in the treatment of chronic pulmonary diseases. However, suboptimal inhalation techniques, including inadequate airflow rates, have been a persistent concern for achieving effective therapeutic outcomes, as many patients remain unaware of their insufficient inhalation performance. As an effective strategy, a digital monitoring system, coupled with dry powder inhalers (DPIs), has emerged to estimate flow profiles and provide inhalation information. The estimation could be further facilitated by the application of artificial intelligence (AI). In this work, a novel digital system to primarily monitor pressure during DPI usage was successfully designed, and advanced machine learning (ML) techniques were then employed to estimate inhalation flow profiles based on the captured data. Four optimal machine learning models were selected for subsequent inhalation parameter prediction, given their superior generalization ability. By using these models, inhalation flow profiles could be successfully estimated, with an excellent accuracy of 97.7% for Peak Inspiratory Flow Rate (PIFR) and 95.2% for inspiratory capacity (IC). In summary, the pressure-based digital monitoring system empowered by AI techniques could be successfully applied to assess inhalation flow profiles with excellent accuracy.
Open AccessDevelopment of an AI-Empowered Novel Digital Monitoring System for Inhalation Flow Profiles
The use of dry powder inhalers (DPIs) represents a cornerstone in the treatment of chronic pulmonary diseases. However, suboptimal inhalation techniques, including inadequate airflow rates, have been a persistent concern for achieving effective therapeutic outcomes, as many patients remain unaware of their insufficient inhalation performance. As an effective strategy, a digital monitoring system, coupled with dry powder inhalers (DPIs), has emerged to estimate flow profiles and provide inhalation information. The estimation could be further facilitated by the application of artificial intelligence (AI). In this work, a novel digital system to primarily monitor pressure during DPI usage was successfully designed, and advanced machine learning (ML) techniques were then employed to estimate inhalation flow profiles based on the captured data. Four optimal machine learning models were selected for subsequent inhalation parameter prediction, given their superior generalization ability. By using these models, inhalation flow profiles could be successfully estimated, with an excellent accuracy of 97.7% for Peak Inspiratory Flow Rate (PIFR) and 95.2% for inspiratory capacity (IC). In summary, the pressure-based digital monitoring system empowered by AI techniques could be successfully applied to assess inhalation flow profiles with excellent accuracy.
- 1 July 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (7) , 1167-1180
Evaluation of the Combination of L‑leucine to Chitosan on Sustained Release of Inhalable Heparin Sodium Microparticles
Objective This study explores the co-spray-drying of chitosan and L-leucine to optimize inhalable microparticles for heparin sodium. Chitosan provides sustained release and pulmonary retention, while L-leucine improves powder dispersibility and aerosolization performance. By tuning the chitosan-to-leucine ratio, the formulation achieves an optimal balance between deep lung deposition and prolonged therapeutic effect, offering a promising strategy for polysaccharide-based pulmonary delivery. Methods Inhalable microparticles were prepared via co-spray-drying of heparin sodium with chitosan and L-leucine. In-vitro aerosolization performance was evaluated using the Next Generation Impactor. Particle morphology was examined via scanning electron microscopy (SEM). Solid-state properties were analyzed using X-ray powder diffraction (XRPD) to assess changes in crystallinity. Stability was assessed at 25 °C and 55% RH over 4 weeks. Drug release was studied using the in-vitro dialysis method and modeled with five kinetic models: Zero-order, First-order, Higuchi, Hixson–Crowell, and Korsmeyer–Peppas. Results Heparin sodium microparticles containing chitosan and L-leucine exhibited favorable aerosolization performance, especially in the HSCL1 formulation. SEM showed that L-leucine-induced wrinkling improved dispersibility, while excess chitosan caused surface cracking. XRPD analysis indicated that chitosan suppressed crystallinity while L-leucine retained partial crystalline features, supporting matrix stability and powder dispersion. In-vitro release study demonstrated biphasic kinetics in chitosan-containing formulations. HSCL1 showed sustained, non-Fickian release and enhanced storage stability. Conclusion Co-spray-dried heparin sodium microparticles with chitosan and L-leucine achieved balanced aerosolization performance, sustained release, and storage stability. Their combination overcomes the limitations of single-excipient systems. The optimized formulation demonstrates strong potential for effective pulmonary drug delivery with improved therapeutic consistency. Graphical Abstract
- 1 July 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (7) , 1167-1180
Evaluation of the Combination of L‑leucine to Chitosan on Sustained Release of Inhalable Heparin Sodium Microparticles
Objective This study explores the co-spray-drying of chitosan and L-leucine to optimize inhalable microparticles for heparin sodium. Chitosan provides sustained release and pulmonary retention, while L-leucine improves powder dispersibility and aerosolization performance. By tuning the chitosan-to-leucine ratio, the formulation achieves an optimal balance between deep lung deposition and prolonged therapeutic effect, offering a promising strategy for polysaccharide-based pulmonary delivery. Methods Inhalable microparticles were prepared via co-spray-drying of heparin sodium with chitosan and L-leucine. In-vitro aerosolization performance was evaluated using the Next Generation Impactor. Particle morphology was examined via scanning electron microscopy (SEM). Solid-state properties were analyzed using X-ray powder diffraction (XRPD) to assess changes in crystallinity. Stability was assessed at 25 °C and 55% RH over 4 weeks. Drug release was studied using the in-vitro dialysis method and modeled with five kinetic models: Zero-order, First-order, Higuchi, Hixson–Crowell, and Korsmeyer–Peppas. Results Heparin sodium microparticles containing chitosan and L-leucine exhibited favorable aerosolization performance, especially in the HSCL1 formulation. SEM showed that L-leucine-induced wrinkling improved dispersibility, while excess chitosan caused surface cracking. XRPD analysis indicated that chitosan suppressed crystallinity while L-leucine retained partial crystalline features, supporting matrix stability and powder dispersion. In-vitro release study demonstrated biphasic kinetics in chitosan-containing formulations. HSCL1 showed sustained, non-Fickian release and enhanced storage stability. Conclusion Co-spray-dried heparin sodium microparticles with chitosan and L-leucine achieved balanced aerosolization performance, sustained release, and storage stability. Their combination overcomes the limitations of single-excipient systems. The optimized formulation demonstrates strong potential for effective pulmonary drug delivery with improved therapeutic consistency. Graphical Abstract
- Open Access
- 1 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 680, 125802
Development of high-dose carrier-free inhalable heparin sodium microparticles using co-jet-milling technology
- 1 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 680, 125802
Open AccessDevelopment of high-dose carrier-free inhalable heparin sodium microparticles using co-jet-milling technology